Follow The Filings

BRKR Bruker Corporation

Health Care, filed as BRUKER CORP (COM), Equity As of 2026 Q2 among managers we track Quote on Google Finance, opens in a new tab

Bought by 3 managers in 2026 Q2

  • 3 Owners
  • Max 3.6%
  • $244M
  • 3 new

In 2026 Q2 Sachem Head Capital Management, Glenview Capital Management, and Andreas Halvorsen opened positions in Bruker.

Who owns this now

Largest portfolio weights among holders, up to 3.6% (Sachem Head Capital Management). Not free-float ownership.

  1. Sachem Head Capital Management New 3.6%
  2. Glenview Capital Management New 0.28%
  3. Andreas Halvorsen New 0.15%

Who owns BRKR

Sorted by value, long equity only, as of 2026 Q2.

History
Sachem Head Capital Management 3.6% New 3.6% 2,915,000 $175M History
Andreas Halvorsen, Viking Global Investors 0.15% New 0.15% 893,491 $54M History
Glenview Capital Management 0.28% New 0.28% 252,169 $15M History

3 current, options excluded

Weight bar: held both quarters added sold at this quarter’s reported price

Insider trades

Open-market buys and sales by BRKR's executives, directors and 10% owners in the last 12 months, from their Form 4s

All BRKR insider trades
  • None no insider bought on the open market
  • $684K sold by 3 insiders outside a trading plan
  • $2.9M sold by 1 insider under 10b5-1 plans
  1. Mark Munch Exec VP&Pres Bruker Nano Inc.
    Planned sale
    $106K 2,000 shares at $52.87 1.5% of stake
    Traded Sep 15 Filed Sep 16
    ↗
  2. Wolfgang Pusch President BMID Group
    Sale
    $198K 3,473 shares at $56.90 26% of stake
    Traded Aug 17 Filed Aug 18
    ↗
  3. Mark Munch Exec VP&Pres Bruker Nano Inc.
    Planned sale
    $115K 2,000 shares at $57.60 1.6% of stake
    Traded Aug 14 Filed Aug 18
    ↗
  4. Mark Munch Exec VP&Pres Bruker Nano Inc.
    Planned sale
    $121K 2,000 shares at $60.25 1.5% of stake
    Traded Jul 15 Filed Jul 16
    ↗
  5. Mark Munch Exec VP&Pres Bruker Nano Inc.
    Planned sale
    $110K 2,000 shares at $54.76 1.5% of stake
    Traded Jun 15 Filed Jun 16
    ↗
  6. Mark Munch Exec VP&Pres Bruker Nano Inc.
    Planned sale
    $88K 2,000 shares at $43.90 1.5% of stake
    Traded May 15 Filed May 18
    ↗
  7. Mark Munch Exec VP&Pres Bruker Nano Inc.
    Planned sale
    $80K 2,000 shares at $39.90 1.5% of stake
    Traded Apr 15 Filed Apr 16
    ↗
  8. Mark Munch Exec VP&Pres Bruker Nano Inc.
    Planned sale
    $71K 2,000 shares at $35.44 1.5% of stake
    Traded Mar 13 Filed Mar 16
    ↗
  9. Mark Munch Exec VP&Pres Bruker Nano Inc.
    Planned sale
    $74K 2,000 shares at $36.94 1.5% of stake
    Traded Feb 13 Filed Feb 18
    ↗
  10. Mark Munch Exec VP&Pres Bruker Nano Inc.
    Planned sale
    $98K 2,000 shares at $49.20 1.5% of stake
    Traded Jan 15 Filed Jan 16
    ↗
  11. Mark Munch Exec VP&Pres Bruker Nano Inc.
    Planned sale
    $385K 7,000 shares at $55.00 5.2% of stake
    Traded Jan 12 Filed Jan 13
    ↗
  12. Mark Munch Exec VP&Pres Bruker Nano Inc.
    Planned sale
    $1.7M 33,843 shares at $49.66 21% of stake
    Traded Jan 5 Filed Jan 6
    ↗
  13. Richard A Packer Director
    Sale
    $243K 5,028 shares at $48.38 5.3% of stake
    Traded Dec 1, 2025 Filed Dec 2, 2025
    ↗
  14. John A Ornell Director
    Sale
    $243K 6,233 shares at $39.00 15% of stake
    Traded Nov 6, 2025 Filed Nov 10, 2025
    ↗

Also filed in the last 12 months, not counted as buying or selling: 18 stock grants, 15 option exercises, and 13 share withholdings for taxes.

Congress

No member of Congress reported trading BRKR in the last three years. 1 member listed it in 2025 annual reports.

All Congress trades

SEC filings

Recent issuer filings from EDGAR, 20 shown.

Filed Form Detail Links
8-K 8.01 Filing Doc
8-K 8.01 Filing Doc
SCHEDULE 13G/A — Filing Doc
10-Q Filing Doc
8-K 2.02,9.01 Filing Doc
8-K 8.01 Filing Doc
8-K/A 5.07 Filing Doc
8-K 5.07 Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 8.01 Filing Doc
10-Q Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 2.02,9.01 Filing Doc
8-K 8.01 Filing Doc
DEF 14A Filing Doc
8-K 5.02 Filing Doc
DEFA14A Filing Doc
8-K 5.02,9.01 Filing Doc
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13G/A — Filing Doc

Source: SEC EDGAR submissions, updated 3 days ago. All on EDGAR

Financials

US-GAAP annual figures by fiscal year, as tagged in Form 10-K. Each value links to its SEC filing.

Income statement

Metric FY2023 FY2024 FY2025
Revenue $2.96B $3.37B $3.44B
Gross profit $1.51B $1.65B $1.58B
Gross margin * 51.0% 49.0% 45.9%
Net income $427.2M $113.1M -$8.6M
Net margin * 14.4% 3.4% -0.3%

Balance sheet

Metric FY2023 FY2024 FY2025
Total current assets $2.16B $2.05B $2.21B
Total non-current assets * $2.09B $3.75B $4.03B
Total assets $4.25B $5.81B $6.24B
Total current liabilities $1.2B $1.28B $1.28B
Total non-current liabilities * $1.63B $2.71B $2.45B
Total equity $1.38B $1.78B $2.46B

Cash flow

Metric FY2023 FY2024 FY2025
Cash from operations $350.1M $251.3M $134.1M
Cash from investing -$0.326B -$1.76B -$0.196B
Cash from financing -$0.193B $1.23B $0.135B
Net change in cash -$157.1M -$304.9M $116.4M

Source: SEC companyfacts (US-GAAP 10-K). A * marks a computed figure, not a single XBRL tag. Fiscal years are as the issuer labels them. Follow The Filings does not adjust or audit these figures.

Ownership over time

13Fs that reported it each quarter. Click a bar for that quarter’s holders.

Further reading

As an Amazon Associate, FollowTheFilings earns from qualifying purchases.

More on the shelf